These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 15048071)
21. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia. Gozzetti A; Candi V; Fabbri A; Schiattone L; Cencini E; Lauria F; Frasconi A; Crupi R; Raspadori D; Papini G; Defina M; Bartalucci G; Bocchia M Leuk Res; 2014 Aug; 38(8):891-5. PubMed ID: 24934847 [TBL] [Abstract][Full Text] [Related]
22. The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature. Lepretre S; Jäger U; Janssens A; Leblond V; Nikitin E; Robak T; Wendtner CM Leuk Lymphoma; 2012 May; 53(5):820-9. PubMed ID: 21992675 [TBL] [Abstract][Full Text] [Related]
23. Rituximab therapy of severe aplastic anemia induced by fludarabine and cyclophosphamide in a patient affected by B-cell chronic lymphocytic leukemia. Castiglioni MG; Scatena P; Pandolfo C; Mechelli S; Bianchi M Leuk Lymphoma; 2006 Sep; 47(9):1985-6. PubMed ID: 17065021 [No Abstract] [Full Text] [Related]
28. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience. Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A; Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442 [TBL] [Abstract][Full Text] [Related]
29. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. Chow KU; Kim SZ; von Neuhoff N; Schlegelberger B; Stilgenbauer S; Wunderle L; Cordes HJ; Bergmann L Eur J Haematol; 2011 Nov; 87(5):426-33. PubMed ID: 21749447 [TBL] [Abstract][Full Text] [Related]
30. [Current concepts in chronic lymphocytic leukemia. Better chances for young patients]. Hallek M; Bergmann M; Goede V; Fingerle-Rowson G; Schweighofer C; Schmitt B; Wendtner CM; Emmerich B MMW Fortschr Med; 2003 Jul; 145(27-28):46-9. PubMed ID: 14587189 [No Abstract] [Full Text] [Related]
31. Charting the path to the cure of chronic lymphocytic leukemia: consolidation strategies currently lead the way. Tam CS Leuk Lymphoma; 2009 Oct; 50(10):1557-8. PubMed ID: 19757304 [No Abstract] [Full Text] [Related]
32. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Dungarwalla M; Evans SO; Riley U; Catovsky D; Dearden CE; Matutes E Haematologica; 2008 Mar; 93(3):475-6. PubMed ID: 18310545 [TBL] [Abstract][Full Text] [Related]
33. [Modern times: back to past, back to future]. Feliu J; Zabalza A; García-Muñoz R; Olavarría E Med Clin (Barc); 2012 Jul; 139(4):180-1. PubMed ID: 22281094 [No Abstract] [Full Text] [Related]
34. [Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab]. Tsukasaki K Nihon Rinsho; 2015 Feb; 73 Suppl 2():632-5. PubMed ID: 25831837 [No Abstract] [Full Text] [Related]
35. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study. Michallet M; Socié G; Mohty M; Sobh M; Bay JO; Morisset S; Labussière-Wallet H; Tabrizi R; Milpied N; Bordigoni P; El-Cheikh J; Blaise D Exp Hematol; 2013 Feb; 41(2):127-33. PubMed ID: 23089183 [TBL] [Abstract][Full Text] [Related]
37. Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab. Gruber M; Fleiss K; Porpaczy E; Skrabs C; Hauswirth AW; Gaiger A; Vanura K; Heintel D; Shehata M; Einberger C; Thalhammer R; Fonatsch C; Jäger U Ann Hematol; 2011 Oct; 90(10):1131-6. PubMed ID: 21617923 [TBL] [Abstract][Full Text] [Related]
38. Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia. Xu W; Miao KR; Zhu DX; Fang C; Zhu HY; Dong HJ; Wang DM; Wu YJ; Qiao C; Li JY Int J Cancer; 2011 May; 128(9):2192-201. PubMed ID: 20635386 [TBL] [Abstract][Full Text] [Related]
39. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group]. Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539 [TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. Li J; Zhi J; Wenger M; Valente N; Dmoszynska A; Robak T; Mangat R; Joshi A; Visich J J Clin Pharmacol; 2012 Dec; 52(12):1918-26. PubMed ID: 22235140 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]